Guardian Pharmacy Services, Inc. (GRDN): Results of Operations and Financial Condition
Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance ATLANTA, August 6, 2026 – Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”) pharmacy services companies, announced toda
How this was made
The 30-second read
Why it matters
Q2 performance showed modest revenue growth, higher Adjusted EBITDA, and a guidance increase for FY 2026. Management also disclosed acquisition completion (Wellness Concepts) and a new greenfield pharmacy launch, plus leadership changes effective July 1, 2026.
Market read
This is a primary earnings and guidance update with concrete FY 2026 ranges, plus disclosed acquisition and operational expansion, which can drive repricing ahead of the conference call.
What to watch
Net income includes a $8.5 million payor-dispute settlement; traders may focus more on Adjusted EBITDA and cash flow quality to judge sustainability of the guidance raise.
Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance
Revenue rose 2% year-over-year despite IRA-related pricing reductions, residents served increased 8%, Adjusted EBITDA increased to $29.7 million from $25.0 million, and the Company raised both its revenue and Adjusted EBITDA outlook for FY 2026.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $351.8 million | – | up 2% year-over-year |
| Residents servedother | approximately 210,000 | – | up 8% year-over-year |
| Net IncomeGAAP | $22.1 million | – | – |
| Adjusted EBITDAnon-GAAP | $29.7 million | – | – |
| Diluted EPSGAAP | $0.34 | – | – |
| Adjusted EPSnon-GAAP | $0.29 | – | – |
| Licensed pharmaciesother | more than 61 licensed pharmacies | – | – |
| Full-service pharmaciesother | 54 | – | – |
FY 2026 outlook
- Revenue$ 1.43 billion - $1.45 billion
- NoteAdjusted EBITDA: $ 129 million -$131 million
- NoteThe guidance below excludes any future acquisitions.
What drove it
- Residents served ended the quarter at approximately 210,000, up 8% year-over-year.
- IRA-related pricing reductions affected reported revenue growth.
- Absent the price reductions from the IRA, revenues would have been up low double digits compared to the second quarter of 2025.
- Management cited benefits of scale, purchasing leverage and improved operating efficiency.
- Subsequent to quarter-end, Guardian completed the acquisition of Wellness Concepts, a long-term care pharmacy based in Grottoes, Virginia.
- Guardian launched a new greenfield pharmacy in Lexington, Kentucky, its first location in the state.
Concerns
- IRA-related pricing reductions affected reported revenue growth.
- Net Income of $22.1 million was inclusive of a $8.5 million settlement related to a payor dispute.
- FY 2026 guidance excludes any future acquisitions.
- The filing identifies risks related to pharmaceutical pricing and reimbursement, managed care and health plan payors, acquisitions, supply chain disruptions, regulatory change, liquidity, and cybersecurity.
What to watch
- Execution against updated FY 2026 revenue guidance of $ 1.43 billion - $1.45 billion.
- Execution against updated FY 2026 Adjusted EBITDA guidance of $ 129 million -$131 million.
- The ongoing effect of IRA-related pricing reductions on reported revenue growth.
- Integration of Wellness Concepts and development of the Lexington, Kentucky greenfield pharmacy.
- Whether resident growth, purchasing leverage and operating efficiency continue to support profitability.
Balance sheet and cash flow
- Cash and cash equivalents totaled $89.8 million at quarter-end.
- No long-term debt outstanding under our credit facility.
Analysis
Guardian reported second-quarter revenue of $351.8 million, up 2% year-over-year, while residents served reached approximately 210,000, up 8% year-over-year. Management attributed the modest reported revenue growth to IRA-related pricing reductions and stated that, absent those reductions, revenue would have been up low double digits compared with the second quarter of 2025. The contrast between resident growth and reported revenue growth makes reimbursement and drug-pricing pressure a central factor in assessing top-line performance.
Profitability improved on the reported non-GAAP measure, with Adjusted EBITDA of $29.7 million compared to $25.0 million in the prior-year period. Management attributed the expansion to scale, purchasing leverage and improved operating efficiency. GAAP Net Income was $22.1 million compared to $8.8 million in the prior-year period, but the current-quarter result included a $8.5 million settlement related to a payor dispute, which is important context for evaluating the GAAP comparison. Diluted EPS was $0.34 and Adjusted EPS was $0.29.
The balance-sheet disclosure reported $89.8 million of cash and cash equivalents at quarter-end and no long-term debt outstanding under the credit facility. Subsequent to quarter-end, Guardian completed the Wellness Concepts acquisition and launched a Lexington, Kentucky greenfield pharmacy. These actions expanded the geographic footprint, but the FY 2026 guidance explicitly excludes any future acquisitions.
Guardian raised FY 2026 revenue guidance to $ 1.43 billion - $1.45 billion from $ 1.40 billion -$1.42 billion and raised Adjusted EBITDA guidance to $ 129 million -$131 million from $ 122 million -$127 million. The updated outlook signals management confidence in its operating trajectory, while future reported revenue growth remains exposed to the IRA-related pricing reductions highlighted in the release.
Management, verbatim
Guardian delivered another strong quarter, with continued momentum across our local markets.
Fred Burke, President and Chief Executive Officer
While IRA-related pricing reductions affected reported revenue growth, which was up 2%, the underlying business remained strong. Absent the price reductions from the IRA, revenues would have been up low double digits compared to the second quarter of 2025. We also continued to expand profitability, reflecting the benefits of scale, purchasing leverage and improved operating efficiency.
Fred Burke, President and Chief Executive Officer
Our second-quarter performance, together with our outlook for the remainder of the year, gives us the confidence to raise our 2026 guidance.
Fred Burke, President and Chief Executive Officer
Not in the filing
stated, not guessed- Revenue prior-year dollar amount
- Revenue prior-quarter amount and sequential change
- Gross profit and gross margin
- Operating income or loss
- Operating expenses
- Adjusted Net Income
- Net income year-over-year percentage change
- Net income prior-quarter amount and sequential change
- Diluted EPS prior-year and prior-quarter amounts and percentage changes
- Adjusted EPS prior-year and prior-quarter amounts and percentage changes
- Adjusted EBITDA year-over-year percentage change and prior-quarter amount
- Weighted-average diluted shares
- Operating cash flow
- Free cash flow
- Capital expenditures
- Share repurchases
- Dividends
- Total debt balance
- Debt maturities
- Cash-flow statement details
- Segment revenue and segment profitability
- FY 2026 gross-margin guidance
- FY 2026 operating-expense guidance
- FY 2026 tax-rate guidance
- Prior-release outlook section for actual-versus-prior-guidance comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Guardian is an LTC pharmacy services provider with a locally based model and a network of licensed pharmacies serving about 210,000 residents as of June 30, 2026.
Ticker impact
Guardian Pharmacy Services reported Q2 results and raised 2026 revenue and Adjusted EBITDA guidance, citing IRA-related pricing reductions.
Likely near-term positive bias as guidance raise can re-rate expectations, with follow-through dependent on whether IRA pricing pressure persists.
The filing is a primary disclosure (8-K with earnings release) including updated FY 2026 ranges and Q2 operating improvements (Adjusted EBITDA up, residents served up).
Market effects
Could support sentiment for LTC pharmacy services names by signaling demand resilience and operating leverage despite reimbursement/pricing pressure.
No specific regional macro impacts disclosed beyond continued local-market momentum and geographic expansion.
Primarily US healthcare reimbursement and LTC operations; limited direct global linkage.
Counterpoint
The company attributes revenue growth to IRA-related pricing reductions, implying reported growth may understate underlying demand but also that pricing headwinds could reappear and cap upside.
Key entities
- companyGuardian Pharmacy Services, Inc.
Subject issuer filing an 8-K with Q2 2026 results and updated FY 2026 guidance.
- companyWellness Concepts
Long-term care pharmacy acquired post quarter-end, expanding Guardian’s footprint in Virginia.
- executiveDavid Morris
Appointed Chief Operating Officer effective July 1, 2026, overseeing pharmacy operations and sales organization.
- executiveWill Mudd
Appointed Chief Financial Officer effective July 1, 2026.
